Key Points
- Insider sale: Subhashis Banerjee sold 8,222 Artiva Biotherapeutics shares at an average price of $12.01, generating $98,746.22 and reducing his position by 5.47% to 142,047 shares.
- Analyst outlook remains positive: Artiva has a consensus “Moderate Buy” rating and an average price target of $39, despite one analyst maintaining a sell rating.
- Stock and financial performance: ARTV opened at $11.30, up 1.9%, while the company reported a quarterly loss of $0.63 per share and analysts expect a full-year loss of $2.62 per share.
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) insider Subhashis Banerjee sold 8,222 shares of Artiva Biotherapeutics stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $12.01, for a total value of $98,746.22. Following the transaction, the insider owned 142,047 shares of the company's stock, valued at $1,705,984.47. The trade was a 5.47% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Subhashis Banerjee also recently made the following trade(s):
- On Tuesday, August 18th, Subhashis Banerjee sold 429 shares of Artiva Biotherapeutics stock. The stock was sold at an average price of $12.00, for a total value of $5,148.00.
Artiva Biotherapeutics Trading Up 1.9%
NASDAQ ARTV opened at $11.30 on Tuesday. Artiva Biotherapeutics, Inc. has a 12 month low of $2.22 and a 12 month high of $14.53. The stock has a market cap of $552.46 million, a P/E ratio of -3.42 and a beta of 2.16. The stock's fifty day moving average price is $10.42 and its 200-day moving average price is $8.58.
Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.63) earnings per share for the quarter, meeting the consensus estimate of ($0.63). As a group, analysts forecast that Artiva Biotherapeutics, Inc. will post -2.62 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several research analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Artiva Biotherapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 8th. HC Wainwright boosted their price target on Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a "buy" rating in a research note on Friday, May 8th. Wedbush increased their price objective on Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an "outperform" rating in a research report on Monday, May 11th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Artiva Biotherapeutics in a report on Tuesday, May 26th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Artiva Biotherapeutics in a research report on Tuesday, July 21st. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $39.00.
Check Out Our Latest Report on ARTV
Institutional Trading of Artiva Biotherapeutics
Several large investors have recently modified their holdings of the company. 5AM Venture Management LLC purchased a new position in Artiva Biotherapeutics in the second quarter worth about $22,827,049. Blue Owl Capital Holdings LP purchased a new stake in shares of Artiva Biotherapeutics during the 2nd quarter valued at about $8,483,000. Citadel Advisors LLC increased its position in shares of Artiva Biotherapeutics by 419.3% during the 3rd quarter. Citadel Advisors LLC now owns 798,397 shares of the company's stock valued at $2,291,000 after purchasing an additional 644,658 shares during the last quarter. BlackRock Inc. bought a new position in shares of Artiva Biotherapeutics in the 2nd quarter worth approximately $6,739,000. Finally, Nantahala Capital Management LLC bought a new position in shares of Artiva Biotherapeutics in the 2nd quarter worth approximately $2,910,000.
About Artiva Biotherapeutics
(
Get Free Report)
Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company's proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.
Artiva's pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
